Event Details
July 24, 2015
Description
The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the marketing authorization of Praluent.
Participants (2)
| Name | Type | Mentions | |
|---|---|---|---|
| CHMP | person | 0 | View Entity |
| Unnamed Female Witness 2 | person | 2 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_026365.jpg
This document is a press release from pharmaceutical companies Sanofi and Regeneron regarding their cholesterol drug, Praluent (alirocumab). It announces the drug's approval based on clinical trial data, its U.S. price of $40 per day, and the launch of patient support programs. The release also advertises an investor relations conference call scheduled for July 24, 2015, and notes a pending marketing authorization decision in the European Union.
Related Events
Events with shared participants
A police officer interviewed a female witness who had been providing massages at Epstein's house since she was sixteen.
2005-10-06 • Undisclosed
The European Medicine Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the marketing authorization of Praluent.
Date unknown
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event